Axovant Sciences Ltd. (NYSE:AXON) Files An 8-K Results of Operations and Financial Condition

Item2.02 Results of Operations and Financial Condition.

On January9, 2017, Axovant Sciences Ltd. (Axovant) issued a
press release providing its estimated cash balance as of
December31, 2016. This amount is preliminary, unaudited and
subject to change upon completion of Axovants review of its
financial statements as of and for the quarterly period ended
December31, 2016. Additional information and disclosures would be
required for a more complete understanding of Axovants financial
position and results of operations as of December31, 2016. A copy
of the press release is attached as Exhibit99.1 to this current
report and is incorporated herein by reference.

In accordance with General Instruction B.2. ofForm8-K,the
information in this Item2.02, and Exhibit99.1 hereto, shall not
be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or
otherwise subject to the liability of that section, nor shall it
be deemed incorporated by reference in any of the Registrants
filings under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date hereof,
regardless of any incorporation language in such a filing, except
as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

About Axovant Sciences Ltd. (NYSE:AXON)

Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company’s focus is to develop its lead product candidate, Intepirdine, which is a selective 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing its second product candidate, Nelotanserin, which is a selective 5-HT2A receptor inverse agonist for the treatment of visual hallucinations in patients with DLB and rapid eye movement (REM) behavior disorder (RBD) in patients with DLB.

Axovant Sciences Ltd. (NYSE:AXON) Recent Trading Information

Axovant Sciences Ltd. (NYSE:AXON) closed its last trading session up +0.08 at 13.26 with 186,342 shares trading hands.